139 related articles for article (PubMed ID: 23635729)
1. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial.
Wong AWY; Chan SSC; Yeo W; Yu MY; Tam WH
Obstet Gynecol; 2013 May; 121(5):943-950. PubMed ID: 23635729
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
3. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
[TBL] [Abstract][Full Text] [Related]
6. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
Gardner FJ; Konje JC; Abrams KR; Brown LJ; Khanna S; Al-Azzawi F; Bell SC; Taylor DJ
Lancet; 2000 Nov; 356(9243):1711-7. PubMed ID: 11095258
[TBL] [Abstract][Full Text] [Related]
7. The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen.
Shi Q; Li J; Li M; Wu J; Yao Q; Xing A
Eur J Gynaecol Oncol; 2014; 35(5):492-8. PubMed ID: 25423691
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
Kesim MD; Aydin Y; Atis A; Mandiraci G
Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.
Fu Y; Zhuang Z
Int J Clin Exp Pathol; 2014; 7(10):6419-29. PubMed ID: 25400720
[TBL] [Abstract][Full Text] [Related]
10. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
11. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
Ewies AA; Alfhaily F
Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
[TBL] [Abstract][Full Text] [Related]
12. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.
Gardner FJ; Konje JC; Bell SC; Abrams KR; Brown LJ; Taylor DJ; Habiba M
Gynecol Oncol; 2009 Sep; 114(3):452-6. PubMed ID: 19576623
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
Lee M; Piao J; Jeon MJ
Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
[TBL] [Abstract][Full Text] [Related]
14. [Tamoxifen, endometrial cancer and levonorgestrel intra-uterine device].
Espié M
Gynecol Obstet Fertil; 2003 Oct; 31(10):867-71. PubMed ID: 14642946
[TBL] [Abstract][Full Text] [Related]
15. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
16. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
Gallos ID; Ganesan R; Gupta JK
Obstet Gynecol; 2013 Jun; 121(6):1165-1171. PubMed ID: 23812448
[TBL] [Abstract][Full Text] [Related]
17. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel-releasing intrauterine devices.
Gerber B; Reimer T; Krause A; Friese K; Müller H
Lancet; 2001 Mar; 357(9258):801. PubMed ID: 11253991
[No Abstract] [Full Text] [Related]
20. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]